On January the 29th CADDAC was notified by Patrick Dicerni, the Assistant Deputy Minister and Executive Officer of the Drugs and Devices Division at the Ministry of Health and Long-Term Care, that Ontario will publicly reimburse INTUNIV XR® (guanfacine hydrochloride extended-release tablets) for the treatment of attention deficit/hyperactivity disorder (ADHD) symptoms in children and adolescents (6 to 17 years old). The medication has been approved as an adjunctive (add on) therapy to stimulant medication and as a stand-alone treatment for those who have significant intolerance to stimulant medication or have had an inadequate response to either atomoxetine or other non-stimulant medications.
CADDAC has advocated for this coverage for some time now and would like to applaud the Ontario government for granting families access to an additional treatment option to help their children manage their ADHD.
Updates on the status of new drug products funded by the ODB program can be found in the Ontario Drug Benefit Formulary on the ministry’s website at: http://www.health.gov.on.ca/en/pro/programs/drugs/edition_43.aspx
A media release from Takeda can be accessed Here